Results 121 to 130 of about 47,729 (258)

Two causes of COVID‐19‐related myocardial injury‐associated cardiogenic shock: Myocarditis and microvascular thrombosis

ESC Heart Failure, Volume 12, Issue 2, Page 1514-1522, April 2025.
Takamasa Iwai, Hirohiko Aikawa, Yoshiaki Morita, Keiko Ohta‐Ogo, Teruo Noguchi   +4 more
wiley   +1 more source

The impact of systemic long‐term medications for the development of age‐related macular degeneration

Acta Ophthalmologica, EarlyView.
Abstract Purpose Age‐related macular degeneration (AMD) is a leading cause of central vision loss in the elderly; however, the systemic factors that modulate its incidence and progression remain unclear. We sought to determine whether long‐term use of systemic medications, including diabetes and antithrombotic medications, corticosteroids and ...
Hanna Heloterä, Reijo Sund, Toni Rikkonen, Kai Kaarniranta   +3 more
wiley   +1 more source

Non‐canonical PKG1 regulation in cardiovascular health and disease

British Journal of Pharmacology, EarlyView.
It is well established that the cyclic GMP‐dependent protein kinase I (PKG1) is canonically activated by cyclic guanosine monophosphate (cGMP), enabling its regulation of vascular tone, cardiac function and smooth muscle homeostasis. However, diverse non‐canonical stimuli of PKG1 have also been identified.
Jie Su, Joseph Robert Burgoyne
wiley   +1 more source

Predicting dialyzer fiber blocking is hard due to high intrapatient variability and limited utility of thrombin generation markers. [PDF]

Sci Rep
Eloot S, Mertens T, Josipovic I, Konings J, Glorieux G, Fredenburgh LE, Roest M, Acosta R, De Somer F, Marin EP, Boone MN, Van Biesen W, Vanommeslaeghe F.   +12 more
europepmc   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, EarlyView.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Emicizumab, the factor VIII mimetic bispecific monoclonal antibody: effects on thrombin generation and thromboelastometry. [PDF]

Res Pract Thromb Haemost
Tripodi A, Clerici M, Scalambrino E, Arcudi S, Gualtierotti R, Novembrino C, Peyvandi F.   +6 more
europepmc   +1 more source

Targeting protein–protein interactions with reversible covalent modalities: Non‐cysteine chemistries

British Journal of Pharmacology, EarlyView.
Abstract Protein–protein interactions (PPIs) are central to diverse cellular functions, and represent a rapidly expanding class of therapeutic targets. Advancements in covalent drug design have enabled small‐molecule drugs to overcome challenges associated with engaging these targets, such as limited durations of action and difficult‐to‐drug (expansive,
Ruchira Basu, Steven Fletcher
wiley   +1 more source

Thrombin generation in HeartMate 3 patients on apixaban and vitamin K antagonists: Variability limits clinical applicability. [PDF]

JHLT Open
Van Edom CJ, Droogné W, Jacobs S, Jacquemin M, Van Laer C, Van Puyvelde J, Vlasselaers D, Vandersmissen K, Vanassche T, Meyns B.   +9 more
europepmc   +1 more source

Renal‐vascular axis: unmasking its role in vascular endothelial growth factor‐inhibitor vascular toxicity in cancer patients

British Journal of Pharmacology, EarlyView.
Abstract Vascular toxicity is a growing concern in cancer patients receiving vascular endothelial growth factor inhibitor (VEGFi) therapy, posing a significant threat to patient prognosis. While the primary mechanism of VEGFi‐induced vascular toxicity is linked to redox‐sensitive reactions that disrupt vascular tone, leading to hypertension and ...
Grace Whelan, Karla B. Neves
wiley   +1 more source

High incidence of thrombin generation resistance to thrombomodulin in patients with unprovoked venous thromboembolism. [PDF]

Blood Vessel Thromb Hemost
Gris JC, Chea M, Nouvellon E, De Jouvancourt R, Fortier M, Bourguignon C, Laurent J, Bouvier S, Perez-Martin A.   +8 more
europepmc   +1 more source